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Executive Summary 
 
For women who inject drugs, the stigma of injection drug use is added to gendered 
discrimination; these factors combined can push women into behaviors that increase their 
risk of HIV.  There is a higher likelihood that women drug users will provide sex in 
exchange for housing, sustenance, and protection; suffer violence from sexual partners; 
and have difficulty insisting that their sexual partners use condoms.  Women drug users 
may also rely on men to inject them with drugs and acquire drugs and injection 
equipment, a behavior shown to increase the likelihood of injection with contaminated 
equipment. 
 
Factors that reduce women drug users’ access to health care include punitive policies, 
discrimination by police and health care providers, the intense social stigma attached to 
drug use by women, a preponderance of harm reduction and drug treatment programs 
directed primarily toward men, an absence of sexual and reproductive health services for 
drug users, and poor access to effective outpatient drug treatment, in which methadone or 
buprenorphine are prescribed to reduce cravings for illicit opiates. 
 
Pregnant drug users are particularly vulnerable. In too many instances, they receive little 
or no accurate information about drug use during pregnancy or prevention of mother-to-
child transmission of HIV.  In some countries pregnant drug users are rejected by health 
care providers, threatened with criminal penalties or loss of parental rights, or coerced 
into having an abortion or abandoning their newborns to the state.  Poor access to 
medication-assisted treatment jeopardizes the pregnancies of opiate-dependent drug 
users.   
 
Increasing women drug users’ access to needed services, including drug treatment, harm 
reduction, and sexual and reproductive health care services, is crucial. Achieving this 
goal requires policies that encourage women to seek drug treatment and harm reduction 
rather than punishing or stigmatizing them for drug use during pregnancy or motherhood;  
increased availability of medication-assisted treatment; incorporation of sexual and 
reproductive health and other women’s services into harm reduction programs;  flexible, 
low-threshold services that are more convenient for women with children; and links 
between harm reduction, drug treatment, women’s shelters, and violence prevention 
services. 
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Challenges Facing Women Who Use Drugs 
 
Gender shapes the experience of drug use and its associated risks.  In most parts of the 
world, however, harm reduction and drug treatment programs that tailor their services to 
meet women’s needs are rare or nonexistent.1  Policies toward drug users tend to ignore 
the needs of women, or, worse, inflict ill-conceived penalties on women who use drugs.  
More research on women drug users is needed.  There is, however, abundant evidence 
that many existing services inadvertently exclude women, and that discriminatory 
policies and social stigma drive women drug users from care and expose them to human 
rights abuses. 
 
This paper, drawing upon evidence from existing studies, examines ways in which 
gender-related factors can increase women drug users’ vulnerability and decrease their 
access to harm reduction, drug treatment, and sexual and reproductive health services.  
The paper makes recommendations to assist researchers, policymakers, and service 
providers in investigating the circumstances women drug users face in their own 
countries and in formulating policies and programs to better serve these women.2   
 
While it reviews research and evidence from around the world, this paper places special 
emphasis on the areas in which the International Harm Reduction Development Program 
(IHRD) of the Open Society Institute works.  For more than a decade, IHRD has worked 
as a donor and advocate to reduce HIV and other harms related to injecting drug use—
particularly opiate injection—and to press for policies that reduce stigmatization of illicit 
drug users and protect their human rights.  IHRD has supported more than 200 harm 
reduction service programs in Central and Eastern Europe and in Asia, focusing on 
countries in which the greatest part of HIV infections are among IDUs.  IHRD advocates 
to expand the availability of needle exchange, high quality drug treatment, and treatment 
for HIV; to reform discriminatory policies and practices; and to increase the political 
participation of people who use drugs and those living with HIV.   
 
This paper limits its scope to HIV and focuses on injecting drug use. It should be noted 
that sharing injecting equipment also increases the risk of other illnesses, such as hepatitis 
B and C, and that in some contexts non-injecting drug use is associated with high risk 
sexual behaviors.3 
 
Growing numbers of women drug users worldwide 
 
According to the United Nations Office on Drugs and Crime (UNODC), about 25 million 
people worldwide are “drug addicts or problem drug users.”4  One percent of the world’s 
                                                 
1 UN Office on Drugs and Crime (UNODC) (2006).  HIV/AIDS prevention and care for female injecting drug users. 
Vienna: United Nations. 
2 Much of the information on women drug users comes from small studies or anecdotal evidence, and circumstances 
vary from country to country and among different cultural, ethnic, and socioeconomic groups. The often fragmentary 
information discussed is not meant to describe the situations of all women drug users.   
3 Winstanley EL, Gust SW, Strathdee SA (2006). Drug abuse and HIV/AIDS: International research lessons and 
imperatives. Drug Alcohol Depend, 2006, 82 Suppl 1:S1-5. 
4 UNODC (2006). World drug report. Vienna: UN. 
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population aged 15-64 use opiates, cocaine, or amphetamine-type stimulants, and about 
13 million users inject.5  Though precise data on women drug users is rarely available, 
women have been estimated to represent about 40 percent of drug users in the United 
States and some parts of Europe, 20 percent in Eastern Europe, Central Asia, and Latin 
America, between 17 and 40 percent in various provinces of China, and 10 percent in 
some other Asian countries.6   In some countries, including China, India, and Russia, 
which are home to a combined 4.6 million of the world’s injecting drug users (IDUs),7 
drug use among women appears to be on the rise, and in many regions more women are 
seeking harm reduction services and drug treatment.8  In recent years, there has been a 
rapid increase in the portion of IDUs who are women, especially in Asia and Eastern 
Europe.9  In China, researchers have documented a rapid increase in the number of 
women IDUs who share injection equipment.10  In Central Asia, drug use is increasing 
rapidly among women.11  Large numbers of women are in need of services to reduce 
drug-related harm, including HIV spread through contaminated injection equipment and 
high risk sexual behavior associated with drug use.   
 
Inattention to women drug users 
 
Research into drug use outside high-income countries has largely neglected women drug 
users.  Many studies have included so few women that analyses of the effects of gender 
are unreliable, while others do not mention gender at all.  National and international 
statistics often do not disaggregate by gender.  For instance, the UNODC’s 2006 World 
Drug Report, which relies in large part on national self-reporting, makes more references 
to the female cannabis plant (14) than to women drug users (5), despite assertions in its 
2005 report that the number of women drug users was increasing and that injection-
driven HIV epidemics were feminizing.   
 
Existing research is in many ways culturally specific and bound by its context.  The vast 
majority of research has been done in North America, Western Europe, and Australia.12  
In developing and transitional countries, women drug users have been overshadowed by 
their male counterparts, who comprise the majority of drug users and clients of harm 
reduction and drug treatment services.  With little information even on the number of 
women drug users in these countries—including those countries experiencing explosive 
                                                 
5 UNODC (2006). World drug report. 
6 UNODC (2004). Substance abuse treatment and care for women: case studies and lessons learned.  New York; UN. 
Xinhua News Agency. (June 25, 2004) Female IDUs, key population for fighting AIDS in China: experts.  In UNODC 
(2005), World drug report. Vienna, UN.  
7 Aceijas, C., Friedman, S. R., Cooper, H. L. F., Wiessing, L., Stimson, G. V., Hickman, M. on behalf of the Reference 
Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries (2006). Estimates of 
injecting drug users at the national and local level in developing and transitional countries, and gender and age 
distribution.  Sexually Transmitted Infections, 82 (suppl_3), iii10-iii17. 
8UNODC (2004).  Substance abuse treatment and care for women. 
9 World Health Organization (WHO).  Where sex work, drug injecting, and HIV overlap.  Forthcoming. 
10 Choi, S.Y.P., Cheung, Y.W., Chen, K. (2006).  Gender and HIV risk behavior among intravenous drug users in 
Sichuan Province, China.  Social Science and Medicine, 62, 1672-1684. 
11 Godinho, J., Renton, A., Vinogradov, V., Novotny T, Gotsadze, G, Rivers, MJ, Bravo, M (2005). Reversing the tide: 
Priorities for HIV/AIDS prevention in Central Asia.  Washington, DC: World Bank.   
12 See Reinarman, C. and Levine, H. (eds.) (1997). Crack in America: Demon drugs and social justice.  Berkeley, 
California: University of California Press.    
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injection-driven HIV epidemics—we can only surmise the complex needs of women who 
use drugs in countries as diverse as Ukraine, China, Malaysia, and Tajikistan.  The one 
exception is IDU sex workers, who have received attention because of their elevated HIV 
risk and potential to act as a so-called “bridge” by which HIV can be transmitted to sex 
worker clients and then to their non-sex worker partners.  Such research is often narrowly 
focused, concentrating on the containment of IDU sex workers as a “vector of disease” 
rather than on the health, safety, and human rights of drug users and sex workers 
themselves.  Moreover, such research may not reflect the needs of the many IDUs who 
are not sex workers.   
 
Women who inject drugs are especially vulnerable 
 
The treatment of women who use drugs reflects society’s expectations and beliefs about 
all women and all drug users, and the problems faced by women who use drugs are often 
amplifications of those faced by other women or by male drug users.  Power imbalances 
related to gender, which are present to varying degrees in virtually all societies, increase 
the vulnerability of women in similar ways, exposing women to abuse, and particularly 
coercion and abuse by male partners.13  On the biological level, women are estimated to 
be twice as likely as men to be infected with HIV during unprotected vaginal 
intercourse.14  This vulnerability combines with stigma against women drug users to 
leave women with reduced access to harm reduction services, drug treatment, and sexual 
and reproductive health care.15   
 
Biological and social factors conspire to increase women drug users’ risk of HIV.  
Studies in nine EU countries showed that the average HIV prevalence was more than 50 
percent higher among women IDUs than it was among their male counterparts.16  It is 
likely that this disparity is even greater in countries without the EU’s relatively well-
developed harm reduction programs.  Studies in Yunnan Province, in China, found that 
HIV prevalence was significantly higher among women IDUs than among male IDUs.17  
In Mombasa, Kenya, a study found that the prevalence of HIV infection was 50 percent 
among all IDUs, but 85 percent among women IDUs.18    
 
The stigma attached to women’s drug and alcohol use, particularly during pregnancy, has 
been documented throughout the world.  In the United States, “crack whore” is a nasty 
insult heard on television and in schoolyards.  In rural Uganda, women who drink alcohol 
in bars are menaced by stories of drunken women who “fall by the roadside” and are 
                                                 
13 Human Rights Watch. (June 2006). UN: AIDS Fight Depends on Respect for Rights. Retrieved May 31, 2007 from 
http://hrw.org/english/docs/2006/06/01/global13496.htm.  Epele, ME (2002).  Gender, violence, and HIV: Women’s 
survival in the streets.  Culture, Medicine and Psychiatry 26: 33–54. 
14Joint United Nations Program on HIV/AIDS (UNAIDS).  Women and girls.   
http://www.unaids.org/en/Policies/Affected_communities/women.asp . Accessed June 26, 2007. 
15 UNODC (2005). World drug report. 
16 European Monitoring Centre for Drugs and Drug Addiction. (2006). Annual report 2006: the state of the drugs 
problem in Europe. Retrieved May 31, 2007 from http://ar2006.emcdda.europa.eu/en/home-en.html 
17 Choi, S.Y.P., Cheung, Y.W., Chen, K. (2006). Gender and HIV risk behavior among intravenous drug users in 
Sichuan Province, China.  Social Science and Medicine, 62, 1672-1684. 
18 Ndetei, D. (2004). UNODC study on the linkages between drug use, injecting drug use and HIV/AIDS in Kenya.  
University of Nairobi, 2004.  In UNODC (2005) World drug report.   
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attacked by men compelled to rape by alcohol.19   Such hostile attitudes promote sexual 
and physical abuse of women drug users, suggesting that those who use drugs do not 
deserve respect.  In a survey across seven regions of Russia, 21 percent of respondents 
said that a wife’s drug or alcohol addiction was a valid reason for her husband to beat 
her.20  It is not uncommon for women drug users to be reluctant to seek care and to report 
crimes committed against them.  Admission of drug use exposes women to harsh 
judgment from health care providers, law enforcement agents, and social networks, and 
after long experience of discrimination many women are justifiably skeptical of any 
positive outcome from a complaint.21  Social stigma and physical and sexual violence 
even lead some women to believe that they deserve abuse, making them even less likely 
to report crimes.22  
 
Women drug users’ disproportionate sexual risk 
 
A growing body of evidence has shown the intimate relationship between sexual and 
injection-related HIV risk among IDUs.  Most IDUs are sexually active, and many 
engage in a range of sexual behaviors that increase their risk of HIV.23  Studies in many 
countries have observed infrequent condom use by IDUs during encounters with sex 
workers, casual partners, and other drug users at risk of HIV through injection.24   Some 
studies have found an association between condom use and avoidance of syringe sharing, 
or between syringe sharing and inconsistent condom use, suggesting that sexual and 
injection-related risk factors are associated.25.  The joint United Nations Programme on 
                                                 
19 Wolff, B., Busza, J., Bufumbo, L., Whitworth, J. (2006).  Women who fall by the roadside: gender, sexual risk and 
alcohol in rural Uganda.  Addiction, 101, 1277-1284.   
20 Gorshkova, ID and Shurigina, II (2003). Violence against women in Russian families. Paper prepared for a 
conference on May 15-16, 2003.  Moscow State University, Lomonosov, Women’s Soviet. Retrieved May 31, 2007, 
from www.womenmsu.msu.ru/apendix/bookall.pdf 
21Murphy, S and Sales, P (2001).  Let’s get real looking at the lives of pregnant drug users.  Harm Reduction 
Communication, Harm Reduction Coalition.  
http://www.harmreduction.org/pubs/news/spring01/sp01murphy_salesp2.html, retrieved February 2007. 
22 Ibid. 
23For example, see: National Aids Center, Belarus (2002). Findings of rapid assessment of HIV and STI among key risk 
groups. Unpublished manuscript.   Initiative for Health Foundation (2004). Injecting drug users in Bulgaria: Profile 
and risks.  Central and Eastern European Harm Reduction Network (CEEHRN) (2005). Sex Work, HIV/AIDS and 
Human Rights in Central and Eastern Europe and Central Asia.  www.ceehrn.org.  Monitoring the Aids Pandemic 
(MAP) (2001).  Status and trends of HIV/AIDS/STI epidemics in Asia and the Pacific. Provisional Report.  Pisani, E, 
Dadun Sucahya, PK Kamil, O and Jazan, S (2003). Sexual behavior among injection drug users in 3 Indonesian cities 
carries a high potential for HIV spread to non-injectors. Journal of Acquired Immune Deficiency Syndrome. 34(4):403-
406.  Choi, SYP et al (2006). Op cit.  MAP (2005).  Drug injection and HIV/AIDS in Asia—MAP Report 2005.  
Geneva: MAP.  Lau, TF, Feng, T, Lin, X, Wang, QH, Tsui, Y (2005). Needle sharing and sex-related risk behaviours 
among drug users in Shenzhen, a city in Guangdong, southern China.  AIDS Care, 17: 2,166-181.   
24 Winstanley, EL, Gust, SW, Strathdee, SA (2006). Drug abuse and HIV/AIDS: International research lessons and 
imperatives. Drug Alcohol Depend, 2006, 82 Suppl 1:S1-5.  UNAIDS (2006), Report on the global AIDS epidemic.  
Op cit.  Rhodes, T, Stimson, GV, Crofts, N, Ball, A, Dehne, K, Khodakevich, L. (1999).  Drug injecting, rapid HIV 
spread, and the “risk environment” implications for assessment and response.  AIDS 13, S259-269.  Lau et al (2005). 
Op cit..  UNODC (2005). Op cit.   Dewing, S, Pluddemann, A, Myers, B, Parry, CDH (2006).  Review of injecting drug 
use in six African countries: Egypt, Kenya, Mauritius, Nigeria, South Africa and Tanzania.  Drugs: education, 
prevention, and policy, 13(2), 121-137. 
25Booth, RE (1995). Gender differences in high risk sex behaviours among heterosexual drug injectors and crack 
smokers. Am J Drug Alcohol Abuse ;21:419-32.  In UNODC (2005). Op cit.  Myers, T, Millson, M, Rigby, J et al 
(1995).  A comparison of the determinants of safe injecting and condom use among injecting drug users.  Addiction 90.   
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HIV/AIDS (UNAIDS) has called for increased provision of sexual health services to 
prevent the spread of HIV to the sexual partners of IDUs.26   
 
A number of studies in the United States have found that sexual practices have a greater 
effect on HIV risk for women IDUs than for males.  In a study in Baltimore, high risk 
sexual activity surpassed risky drug use practices as the main predictor of HIV infection 
among IDU women during the period observed.  HIV incidence more than doubled 
among women IDUs who had an IDU sex partner.27  In a San Francisco study of young 
IDUs, women were more likely than men to have had a recent sexual partner, to have a 
steady partner, and to report that they did not always use a condom during vaginal or anal 
sex.28  This variance is likely due to a greater correlation between women’s drug use and 
high risk sexual practices,29 and to the fact that women are more easily infected through 
vaginal sex.30  In a number of countries, women drug users are more likely to have IDU 
partners and inject with them, at times injecting after a partner who may be HIV-
positive.31  Some studies have shown that women IDUs’ social networks contain more 
IDUs than do those of male injectors and that there is greater overlap between women’s 
sexual and injection networks, perhaps because women’s drug use is more stigmatized 
and thus more isolating than men’s.32   A study of young Los Angeles injectors showed 
that women were more likely to have sexual partners and friends who were also IDUs, 
putting them at greater risk of HIV.33   
 
Obstacles to condom use 
 
A number of factors make it difficult for women to insist that their partners use 
condoms.34  These factors include sexual and domestic abuse,35 fear of abandonment, 
                                                 
26 UNAIDS (2006).  Report on the global AIDS epidemic.  Op cit. 
27 Strathdee, S, Galai, N, Safaiean, M et al. (2001). Sex differences in risk factors for HIV seroconversion among 
injecting drug users: A 10-year perspective. Arch Intern Med, 161.  
28Evans, JL, Hahn, JA, Page-Shafer, K, Lum, PJ, Stein, ES, Davidson, PJ, & Moss, AR (2003). Gender differences in 
sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study).  J Urban 
Health, 80(1), 137-146.   
29 Freeman, RC, Rodriguez, GM, and French, JF (1994). A comparison of male and female intravenous drug users' risk 
behaviors for HIV infection. Am J Drug Alcohol Abuse, 20(2), 129-157. Evans et al.  (2003). Op cit.  Riehman, KS, 
Kral, AH, Anderson, R, Flynn, N, & Bluthenthal, RN (2004). Sexual relationships, secondary syringe exchange, and 
gender differences in HIV risk among drug injectors. J Urban Health, 81(2), 249-259.  Gossop, M, Griffiths, P, Strang, 
J (1994). Sex differences in patterns of drug taking behaviour. A study at a London community drug team.  Br J 
Psychiatry, 164(1), 101-104.  Breen et al (2005).  Op cit. 
30 UNAIDS.  Women and girls.  Op cit.   
31 Rhodes, T, Platt, L, Filatova, K, Sarang, A, Davis, M, & Renton, A (2002). Behaviour factors in HIV transmission in 
Eastern Europe and Central Asia. Geneva: UNAIDS.  Berezhnova, I et al. (2006). HIV/AIDS behavioral risk among 
women using drugs. XVII International conference on the reduction of drug related harm. Vancouver, Canada.  Gore-
Felton, C, Somlai, AM, Benotsch, E, Kelly, JA, Ostovski, D, Kozlov, A (2003). The influence of gender factors 
associated with HIV transmission risk among young Russian injection drug users. The American Journal of Drug and 
Alcohol Abuse, vol. 29, No. 4, pp. 881-894.  UNAIDS Program Coordinating Board (2007).  Assessing Gender 
Equality and Equity as Critical Elements in National Responses to HIV: Cambodia, Honduras and Ukraine.  Geneva. 
32 Doherty, MC, Garfein, RS, Monterosso, ER et al. (2000). Correlates of HIV infection among young adult short-term 
injection drug users.  AIDS,  14, 717-726.  Latkin, CA, Mandell, W, Knowlton, AR et al.  (1998). Gender differences in 
injection-related behaviors among injection drug users in Baltimore, Maryland.  AIDS Educ Prev,10, 257-263. 
33Montgomery, SB, Hyde, J, Johnson De Rosa, C et al. (2002) Gender differences in HIV risk behaviors among young 
injectors and their social network members.  Am J Drug Alcohol Abuse, 28(3), 453-475.    
34 UNAIDS (2006).  Report on the global AIDS epidemic.  Op cit. 
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cultural expectations about male desire and female acquiescence, and poverty.  The latter 
is particularly true in instances that involve the exchange of sex for food, housing, or 
drugs (see discussion of transactional sex below).  For some women IDUs, as for many 
women who are not IDUs, requesting that a partner use a condom can result in 
accusations of infidelity or in violence. For some married women, a request that a 
husband use a condom is out of the question.  In the words of one Vietnamese woman 
married to an IDU who shared injection equipment and did not use condoms: “He is a 
man and the husband of the family; I am the wife, so I must obey him and let him do 
what he wants…husband and wife should share life and death.”36  Women drug users are 
disproportionately likely to experience sexual and physical violence, including childhood 
sexual abuse.37  This can include sexual violence and exploitation by police.38  The 
experience of violence influences not only drug use, which is often a way of coping with 
trauma, but HIV risk, since women in abusive relationships and women experiencing 
sexual violence often do not have the option of insisting on condoms, and because the 
trauma, disempowerment, and loss of self-esteem associated with such violence can make 
it more difficult for women to avoid high risk sex.39  Other IDUs, like many non-IDUs, 
are in steady sexual relationships in which condoms do not seem necessary or desirable. 
Across a wide range of countries, women IDUs are more likely than male IDUs to have a 
steady partner who is an IDU,40 which puts women at disproportionate risk of sexual 
transmission of HIV when condoms are not used.   
 
Transactional sex and commercial sex work41 
 
Poverty and an absence of employment opportunities make transactional sex a survival 
strategy for some women who use drugs.42  Women may have sex with someone who 
gives them a place to stay, food, drugs, or protection.  Compared to commercial sex 
                                                                                                                                                 
35Miller, M (1999).  A model to explain the relationship between sexual abuse and HIV risk among women.  AIDS 
Care, 11(1).  El-Bassel, N, Gilbert, L, Wu, E, Chang, M, Gomes, C, Vinocur, D, Spevack, T (2007).  Intimate partner 
violence prevalence and HIV risks among women receiving care in emergency departments: implications for IPV and 
HIV screening.  Emergency Medicine Journal. Apr;24(4):255-9.  Braitstein, P, Li, K, Tyndall, M, et al (2003).  Sexual 
violence among a cohort of injection drug users.  Social Science & Medicine; 57(3):561-9. 
36 Go, V, Quan, VM, Voytek, C, Celentano, D, Nam, LV (2006). Intra-couple communication dynamics of HIV risk 
behavior among injecting drug users and their sexual partners in northern Vietnam.  Drug and Alcohol Dependence, 84, 
69-76. 
37 Braitstein, P (2003). Op cit.  UNODC (2004).  Substance abuse treatment and care for women.  Op cit.   
38 Charitable Foundation "Kolodets” (2006).  Narkopolitika v Rossii.  Moscow: International Harm Reduction 
Development Program of the Open Society Institute.    Human Rights Watch (2003).  Fanning the flames: How human 
rights abuses are fueling the AIDS epidemic in Kazakhstan.  New York, www.hrw.org.   
39 Miller, M. (1999).  Op cit. 
40 Among the many studies documenting this: Bronzan, RN, Zhussupov, B, Favorov, M, Kryukova, V, Muratbayeva, 
G, Kuznetsov, N, Shakarishvili, A & Ryan, CA (2004). Risk factors for HIV infection among injection drug users in 
Kazakhstan: implications for prevention intervention.  XV International AIDS Conference. Bangkok, 2004.  Gore-
Felton et al (2003). Op cit. Rhodes, T et al (2002). Op cit. Davies, AG, Dominy, NJ, Peters, AD, Richardson, AM 
(1996). Gender differences in HIV risk behaviour of injecting drug users in Edinburgh, AIDS CARE, 8(5).  Personal 
communication, Faranak Chamanyzadeh, Rangin Kaman, Persepolis, 2007; Evans et al (2003) Op cit. 
41 This paper considers sex work only in the context of drug use, and will not delve into the health and human rights 
issues around sex work unrelated to drug use.  For publications and links to organizations that address the health and 
human rights of sex workers, please visit the website of OSI’s Sexual Health and Rights Project at 
http://www.soros.org/initiatives/health/focus/sharp/ 
42 Maher, L (1997).  Sexed work: Gender, race, and resistance in a Brooklyn drug market.  New York: Oxford 
University Press.  Taylor A (1993).  Women drug users: An ethnography of a female injecting community.  Oxford: 
Clarendon Press.   
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work, transactional sex is less likely to take the form of an explicit exchange of goods for 
services, and is more likely to be framed in terms of gratitude, indebtedness, trust, and 
dependence, which can leave little space for women to insist that their partners use 
condoms.  Moreover, the choice between food or shelter and safer sex is not a free one, 
since almost all people will choose daily survival over protection from HIV, a 
comparatively abstract risk.43   
 
In some parts of the world, there is also a substantial overlap between commercial sex 
work and injecting drug use.  It is estimated that between 20 and 50 percent of women 
IDUs in Eastern Europe and between 10 and 25 percent of women IDUs in Central Asia 
are involved in sex work.44  In a study of 82 women IDUs in Sichuan, China, 47 were sex 
workers,45 and 21 percent of women IDU participants in a study in Yunnan were sex 
workers.46   Research suggests that drug- using sex workers, like drug users involved in 
transactional sex, have less freedom to practice safe sex than their non–-drug-using peers. 
For those who become sex workers primarily to support their drug addiction, commercial 
sex work has much in common with transactional sex, with the same absence of genuine 
choice in the face of urgent need.47  This absence of options translates into higher levels 
of HIV: in many places, HIV prevalence among IDU sex workers is higher than it is 
among either non–sex worker IDUs or non-IDU sex workers.48  Finally, if sex workers 
are identified as IDUs it can reduce their earning power and make it more difficult for 
them to attract clients.  This can make them reluctant to be seen at harm reduction sites, 
and thus reduce their access to services. 
 
Drug-using sex workers often engage in higher risk forms of sex work.  This is largely 
because of the financial pressures imposed by poverty and the need to support their own 
and sometimes their partners’ habits, and because IDUs are seen as undesirable and at 
high risk of HIV, and are therefore often excluded from brothels.49  In Asia, Russia, and 
Ukraine, studies have found that IDU sex workers are more likely than non-IDUs to work 
on the street50 and to experience violence from their clients.51  Drug-using sex workers 
may also engage in riskier drug use practices than sex workers who are not IDUs; for 
example, studies in Russia and Bangladesh, among other places, have shown that IDU 
                                                 
43 Epele, ME (2002).  Op cit. 
44 Rhodes, T et al (2002).  Op cit. 
45 Choi, SYP et al (2006).  Op cit. 
46 MAP (2005).  Drug injection and HIV/AIDS in Asia.  Geneva: MAP.   
47 Epele, ME (2002).  Op. cit. 
48 See citations in “Transactional sex and commercial sex work.” 
49 Tran, TN, Detels, R, Hien, NT, Long, HT, Ngad, PTH (2004). Drug use, sexual behaviours and practices among 
female sex workers in Hanoi, Viet Nam—a qualitative study. International Journal of Drug Policy 15. 189–195. 
Burrows, D, Sarankov, Y, Sarang, A (1999). HIV/AIDS prevention, treatment, care and support in the Ukraine. Kiev: 
Medecins Sans Frontieres.  Rhodes, T, Mikhailova, LA, Lowndes, C, et al (2002). Preventing HIV infection among 
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National Institute on Drug Use. Global Research Network.  Meeting on HIV Prevention in Drug-Using Populations: 
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sex workers are more likely than non–sex worker IDUs to engage in risky injecting 
practices.52   
 
One result of these differences is dramatically increased HIV rates among IDU sex 
workers.  In Ukraine, sentinel surveillance data found that HIV prevalence among IDU 
sex workers varied from 8.3 percent to 100 percent depending on the study site, as 
compared to 0 to 21.1 percent among non-IDU sex workers.53  In Hanoi, a study found 
that 33 percent of IDU sex workers were HIV-positive, as opposed to 1.6 percent of non-
IDU sex workers,54 and a study in Ho Chi Minh City found that HIV rates among IDU 
sex workers were more than twice those among non-IDU sex workers.55  In China, 
compared to non-IDU sex workers, IDU sex workers have more clients, use condoms less 
often, and are more likely to share syringes.56  According to a 2002 study in St. 
Petersburg, 30 percent of women IDU sex workers were HIV positive, as opposed to 20 
percent of women IDUs who were not sex workers.57   
 
The greater likelihood that IDU sex workers will be street-based may also increase the 
likelihood that they will have IDU clients, and evidence from many regions of IDUs’ 
inconsistent condom use58 suggests that this is a particularly high risk activity.  This is 
illustrated by a study in Hanoi, which showed that street-based sex workers’ poverty 
forced them to accept drug user clients who were rejected by higher status sex workers.  
The street-based sex workers were more likely to have sex without a condom if offered 
more money, though they made an effort to use condoms with drug users.  Male IDUs 
reported frequent visits to sex workers and low condom use, explaining that they did not 
use condoms in part because they felt that the risk of HIV infection through sex without 
condoms was irrelevant compared to the much greater risk of contracting HIV through 
drug injection59  A sex worker’s injecting drug use may be linked with a higher 
                                                 
52 Platt, L, Rhodes, T, Lowndes, CM, et al (2005).  Impact of gender and sex work on sexual and injecting risk 
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53 UNAIDS Program Coordinating Board (2007).  Op cit.   
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proportion of IDU clients: in Iran, a service provider reports that women sex workers 
who are IDUs usually have only IDU clients..60  
 
Poor sexual and reproductive health services for IDUs 
 
Despite evidence of the link between sexual and injection risk behaviors, integrated 
interventions are relatively unusual in many parts of the world.  Even in San Francisco, a 
city with a well-developed harm reduction movement, a study found that high-coverage 
syringe exchange programs had achieved drastic reductions in injection-related HIV risk 
behavior, but that IDUs continued to be infected with HIV because they did not have 
access to sexual health services that addressed their needs. While IDUs were receiving 
strong messages about preventing HIV through unsafe injection, and were given the 
means to do so, sexual health messages and services were aimed largely at gay men or 
the general population, and were not reaching drug users.61   
 
In Eastern Europe and Central Asia, sexual and reproductive health services for drug 
users are rare, and often operate on a very small scale.  Even sexual health services for 
the general population are poorly developed, and it is safe to assume that IDU women 
have drastically reduced access to these services.  High STI rates in some countries of the 
region—particularly Russia—suggest widespread HIV risk behavior.62  A lack of high 
quality, affordable STI services likely increases STI prevalence and allows STIs to go 
untreated.63  This, too, disproportionately affects women, who are biologically more 
vulnerable to STIs, and for whom untreated STIs increase the risk of HIV.64   
 
In some countries of Eastern Europe and Central Asia, those who test positive for STIs 
are registered as STI “carriers,” and hospitalized for STIs that most countries treat on an 
outpatient basis.  In some Central Asian countries, those who test positive for STIs are 
subject to compulsory treatment for up to 28 days and required to provide the names of 
their sexual partners for notification.  The police are involved in the notification process, 
which can extend to employers and community members.65  The prospect of registration 
and hospitalization may deter many patients, whether or not they are women or drug 
users, from seeking treatment.  Stigma, the absence of drug treatment, and the need to 
seek drugs daily to prevent withdrawal can create overwhelming obstacles to 
hospitalization for drug users.  
 
 
 
                                                 
60 Personal communication, Faranak Chamanyzadeh, Rangin Kaman/Persepolis NGO, 2007. 
61 Kral, AH, Bluthenthal, RN, Lorvick, J, Gee, L, Bacchetti, P, Edlin, BR (2001). Sexual transmission of HIV among 
injection drug users in San Francisco, USA: risk-factor analysis.  Lancet, Vol. 357.   
62 WHO Regional Office for Europe.  Centralized information system for infectious diseases (CISID).  
http://data.euro.who.int/cisid/?TabID=131338.  Retrieved May 27, 2007. 
63 Dehne, KL, Riedner, G, Neckermann, C, Mykyev, O, Ndowa, FJ, Laukamm-Josten, U (2002). A survey of STI 
policies and programmes in Europe: preliminary results.  Sex Transm Inf, 78, 380-384.   
64 Nusbaum, MR, Wallace, RR, Slatt, LM, Kondrad, EC (2004). Sexually transmitted infections and increased risk of 
co-infection with human immunodeficiency virus.  J Am Osteopath Assoc, 104(12), 527-35. 
65 Wolfe, D, Elovich, R, Boltaev, A, Pulatov, D.  HIV in Central Asia: Tajikistan, Uzbekistan, and Kyrgyzstan.  In 
Public Health Aspects of HIV/AIDS in Developing Countries: Epidemiology, Prevention and Care.  In press.   
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Injection risk 
 
Women drug users’ heightened sexual risk is intertwined with an increased risk of 
contracting HIV through shared injection equipment.  Research indicates that a 
significant number of women begin injecting drugs in the context of a sexual 
relationship66 and that women are more likely than men to borrow or share injection 
equipment,67 particularly with their sexual partners.68  According to a cross–sectional 
study in Russia, 24 percent of women IDUs reported sharing injection equipment with 
their IDU sexual partner, compared to 11 percent of male IDUs.69  Some studies have 
found that women are more likely to report that someone else injected them with drugs, 
which has been found to be an independent predictor of HIV incident infection, and, in 
cases in which the injecting partner is male, women often inject last using shared 
equipment.70  One study showed that women in San Francisco were more likely to pool 
money to buy drugs,71 which suggests financial restraints and group injecting that may 
increase HIV risk behavior. According to the study, women’s more frequent risky 
injecting practices were linked to their sexual partnerships with IDUs, though they were 
more likely to be injected by another IDU regardless of their sexual partnerships.72  Some 
women IDUs stay at home to inject73
 
and rely on their male partners for drugs and 
injection equipment, which can make it especially difficult for them to avoid used 
injection equipment and unprotected sex,74 or to access other services.   
 
For women IDUs who share equipment with their partners, questions of intimacy and 
trust that inhibit condom use between steady sexual partners can also increase the 
likelihood of syringe sharing.  A study of women IDUs and IDU couples in Scotland 
showed that love, trust, and intimacy were the most frequently cited reasons for the 
women to share needles and not use condoms with their male partners.75  The power 
imbalances that make it difficult for women to enforce condom use can also make it 
difficult to avoid sharing injection equipment; if a woman is economically dependent on 
a man or being abused by him, for instance, it may be too dangerous for her to refuse to 
                                                 
66 Doherty, MC, Garfein, RS, Monterroso, E, Latkin, C, Vlahov, D (2000). Gender difference in the initiation of 
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retrovirology, 13, 273-80. 
71 Evans (2003). Op cit. 
72 Ibid. 
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75 Ibid. 
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use his syringe after he does.  On the physiological level, women’s smaller surface veins 
make them more likely to need help injecting76 and thus to share injection equipment. 
Finally, a history of sexual violence is associated with a variety of risks, including those 
that are drug-related.  In a Vancouver study of 932 male and 505 female IDUs, 68 percent 
of women and 19 percent of men reported a history of sexual violence.  Study 
participants with a history of sexual violence were more likely to have been in the sex 
trade, to knowingly share injecting equipment with HIV-positive people, to have 
attempted suicide, to have accidentally overdosed, and to have been diagnosed with a 
mental disorder/disability.77 
                                                                                                                                                                              
Bourgois, Prince, and Moss’ ethnographic investigation into the increased risk of 
hepatitis C infection among homeless IDU women in San Francisco provides insight into 
some of the factors that increase women’s injection-related risk.  Bourgois et al. suggest 
that “patriarchal cultural scripts” increase women’s risk by causing them to be injected by 
their partners and to allow their partners to purchase their drugs (though the women often 
pay for them).  Young women new to a drug scene at first have easy access to resources, 
as older men compete to partner with them.  Women’s vulnerability to violence makes it 
preferable for them to partner with a man: though violence from partners is 
commonplace, it is a single, familiar threat that replaces attacks from many sides.  In 
exchange for a measure of protection, men receive financial support through women’s 
sex work, shoplifting, or drug dealing.  Control of a woman’s drug use becomes a way 
for a man to control her financial resources.  Men get the drugs, prepare them, and inject 
them.  The men sometimes inject first and then inject their partner with the used needle, 
or they prepare the drugs out of sight so that their partners cannot tell whether they are 
using a clean syringe.78     
 
Transgender women and women who have sex with women 
 
The disfavored and often illegal status of transgender women and women who have sex 
with women (WSW) reduces their access to health care from nondiscriminatory providers 
who will give them care and information appropriate to their needs,79 and reduces their 
leverage when bargaining for safer sex and clean injecting equipment.80  There is very 
limited research on WSW and transgendered women who use drugs, but existing 
evidence suggests this discrimination puts them at heightened risk of HIV.   
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Research from the United States confirms a fairly high prevalence of same-sex sexual 
behavior among women IDUs81 and a high prevalence of risky sexual and drug use 
practices among drug-using WSW.82  A study in New York and Boston investigated 
markedly higher HIV rates among WSWs83 than among other injectors, and attributed the 
elevated rates to multiple forms of marginalization that promoted unsafe sexual and 
injection practices.84  Another study in the United States found that over 50 percent of 
231 women who had reported female sex partners in the last month had also had sex with 
men. Of these, 70 percent had not used condoms for vaginal sex and 74 percent had not 
for anal sex.  Over 66 percent had shared injection equipment, and 53 percent had shared 
needles.85   
 
Similarly, studies in the United States have shown that the risk factors driving HIV 
transmission in transgender people include social stigma, transactional sex for survival 
needs, and lack of regular, informed, confidential, and nonstigmatizing medical care. One 
1991 study found higher seroprevalence rates among transgender people than among 
nontransgender groups, including IDUs.86  Studies have also found evidence of risky 
behavior during illicit drug, hormone, and silicone use.  In a 2002 study of 81 transgender 
participants, 8 of the 12 respondents who reported a history of injecting drug use said 
they had used a needle that was not new or clean.87  For a variety of reasons, notably lack 
of access to affordable, legal hormone therapy and plastic surgery, some transgender 
women use contaminated needles for illicit hormone or silicone injections, putting them 
at risk of HIV and other blood-borne illnesses.88   
 
Drug use, pregnancy, and motherhood 
 
Ill-informed and punitive policies, ferocious stigma, and lack of access to accurate 
information jeopardize the health of women drug users and their children.  Media 
rhetoric, popular belief, and some health care providers promote the idea that any drug 
use, including drugs used in medication-assisted treatment, precludes the possibility of a 
healthy pregnancy, despite evidence that it is not the fact of drug use but rather 
withdrawal and the degree, type, and timing of drug use, as well as other secondary 
factors that have a profound effect on the outcome of a pregnancy.89  Researchers have 
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found that many of the health problems and behaviors once attributed to prenatal 
exposure to cocaine are in fact the result of malnutrition, lack of sleep, lack of medical 
care, tobacco and alcohol use, and lack of early mother-child bonding due to isolation of 
babies in specialized units.90  Good prenatal care, a healthy diet, drug treatment, and other 
forms of support allow women drug users to give birth to healthy babies.  Medication-
assisted treatment with methadone or buprenorphine, which are safe for use during 
pregnancy, is essential in helping opiate users to avoid withdrawal, overdose, HIV 
transmitted through unsafe injection, and other drug-related risks that endanger the health 
of a woman and her fetus.  (See section on designing drug treatment services for women.)   
 
Because regular opiate use and the poor nutrition and stress associated with many types 
of habitual illicit drug use can cause amenorrhea, the cessation of monthly menstrual 
flow, women drug users may not know they are pregnant for several months.  Vomiting, 
nausea, and other signs of pregnancy may seem unremarkable for a drug user, and some 
assume that drug use prevents conception and obviates the use of contraception.  As a 
consequence, women may not attempt to enter drug treatment, safely reduce drug use, or 
improve nutrition and sleep habits until the third trimester, when such risk-reduction 
strategies are least effective and most potential injury to the fetus has already been done.  
In many countries, the third trimester is also too late for women to choose to have an 
abortion, should they wish to do so.  The stigma of drug use during pregnancy also 
encourages women to conceal their drug use from providers, similarly limiting their 
access to harm reduction information and specialized care.91   
 
Myths and half-truths about drug use during pregnancy can spur pregnant drug users to 
try to cease all drug use abruptly and without medical support, inadvertently causing 
injury to their fetus through withdrawal.  If a woman relapses or is unable to abstain, she 
may assume that all is lost and that nothing more can be done to protect her fetus.92  
Some women respond to this artificially imposed dilemma by remaining in denial about 
their pregnancy until the last moment, giving them little opportunity even to consider 
services to prevent mother-to-child transmission of HIV (PMTCT), drug treatment, or 
risk reduction strategies.93  Failure to provide pregnant women drug users with harm 
reduction, drug treatment services, and other medical and social support is particularly 
regrettable since pregnancy is often a powerful motivator to reduce problematic drug use 
and related harms,94 and is an excellent opportunity for providers to offer care that can 
lead to long-term changes in drug use and lifestyle that can protect women’s health long 
after their baby is born.   
 
Pregnant drug users face stigma and vilification from every side.  Hostility in the media 
and in the popular imagination is compounded by hostility from health care providers, 
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93 Ibid. 
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family members, and even other drug users.  Accounts of pregnant drug users in San 
Francisco and in Glasgow found that partners became abusive or violent when women 
continued using drugs during pregnancy, that drug dealers sometimes refused to sell to 
women who were visibly pregnant, and that partners, family, and friends pressured 
women to abort.95  The stigma attached to a pregnant drug user can force women into 
riskier practices such as injecting alone, paying someone else to buy them drugs, 
concealing their pregnancy, and engaging in the most marginal, high risk forms of sex 
work.96 
 
In the United States, drug-using women have been shackled immediately after childbirth, 
arrested, and tried in court for endangering their unborn children.97  In 2004, a woman 
from South Carolina was charged with murder after cocaine was found in her stillborn 
baby’s system.  She was convicted and is now serving a 12-year sentence.98  In the 
United States, Canada, and some Western European countries, detection of a mother’s 
drug use is often a central factor in her loss of custody.  As a consequence, some women 
avoid contact with health care providers, giving birth outside hospitals or not seeing a 
doctor until they go into labor.99 
 
In other countries, including Russia and Ukraine, drug-using or HIV-positive women are 
pressured or coerced to abort or to give up their children to the care of the state, and are 
denied accurate information about PMTCT or drug use and treatment during 
pregnancy.100   This, along with drug user registration, reduces women drug users’ access 
to drug treatment and PMTCT.  In Russia, pregnant women with HIV who do not seek 
prenatal care before delivery are often active drug users or sex workers.101  In Irkutsk, 
Russia, Kiev, Ukraine, and in other places, it has been reported that IDU women do not 
seek prenatal care, arriving at birthing centers (roddom) only when they are already in 
labor.102  In 1996–2001, most HIV-infected infants in Ukraine and the Russian Federation 
were born to mothers who were either injecting drug users or sexual partners of injecting 
drug users.103  And in Poland, only 50 percent of pregnant drug-using women receive 
prenatal care; a six-month study in obstetric clinics found that of those who identified 
themselves as drug users during delivery, 54 percent were HIV positive.104  It has been 
argued that the encouragement and coercion to abandon children is the product of a 
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Soviet ideology that values institutionalization over individual care and promotes the 
replacement of the family by the state.105 
 
The story of one Thai drug user, interviewed in 2002 by human rights researchers, 
illustrates some of the anguish, desperation, and violent stigma faced by so many 
pregnant drug users: 
 
She lived under a rickety bamboo and corrugated tin shack in Bangkok’s biggest and most drug-
plagued slum…. She was seven months pregnant and had never been to a doctor out of fear of 
being seen as a bad woman.  When she walked down the street, she got derogatory looks and 
catcalls for being a junkie.  She tried to avoid going anywhere, and lived among garbage, rusty 
nails, animals, and brackish water underneath a house, where her boyfriend injected her with 
heroin. She was desperately afraid for her unborn children (in the end, she had twins), and didn’t 
know anything about methadone, thinking it might harm her fetus.  [Researchers] provided her 
with the information that methadone is not harmful in pregnancy, but that reducing her cigarette 
smoking would be enormously beneficial, which made her glad to know that she could do 
something immediately and on her own.106 
 
Punitive policies and stigma toward pregnant drug users have tragic and at times lethal 
effects on women and their children, driving women away from the services that will 
allow them to have healthy babies and make positive changes that will help them be 
healthy mothers.   
 
Punitive drug policies, incarceration, and police abuse 
 
In many countries with injection-driven HIV epidemics, stigmatizing, punitive public 
policies discourage drug users from seeking services.107  Harsh drug policies have a 
disproportionate impact on women: according to UNODC, the proportion of drug users 
among female prisoners is higher than among male prisoners, injecting drugs with shared 
equipment is particularly common among female prisoners, and the HIV rate among 
female prisoners is higher than it is among male prisoners.108   In the United States, the 
country with the world’s highest rate of incarceration, harsh drug policies have increased 
the number of women in prison by as much as 888 percent between 1986 and 1999.109  
Drug possession and complicity in drug transactions often carry heavy penalties,110 and 
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women who are carrying drugs only for personal use or are in the vicinity of a partner or 
family member’s drug dealing receive substantial prison sentences that separate them 
from their families, expose them to an array of physical and psychological harms, and 
reverberate through the rest of their lives.111  In some countries, including the United 
States, Russia, and Georgia, those convicted of drug offenses or identified as drug users 
can suffer consequences that include denial of public housing and other benefits, 
increased risk of losing custody of their children, and discrimination from employers, 
doctors, courts, and educational institutions.112  Imprisonment further increases the HIV 
risk of a group that is already many times more likely than women in the general 
population to experience addiction, have a history of sexual and physical abuse, and 
suffer from mental illness.113  Female prisoners have reported widespread sexual abuse 
by guards, another potential HIV risk and a clear human rights abuse.114  Women in 
prison may also face reduced access to life-saving medical care.  Compared to men, 
incarcerated women in the United States have higher rates of HIV, hepatitis C, and 
serious mental illnesses, yet can be denied even basic medical services, including prenatal 
care.115   
 
Criminalization of possession of drugs for personal use also exposes drug users to police 
abuse, and can make it difficult or impossible for users to report crimes.  Women drug 
users are especially vulnerable to such abuse, which can take the form of sexual 
exploitation.  In Kazakhstan, police come to drug-dealing points to conduct body cavity 
searches, which women IDUs report lead to sex in exchange for the return of seized 
drugs.116  In Russia, Ukraine, and other countries, reported abuses of drug users include 
extortion by the police, denial of access to legal counsel, drug withdrawal used as torture, 
and involuntary HIV testing.117  These all constitute serious human rights violations118 
                                                 
111 The health risks of incarceration are by no means limited to women.  Prisoners in most parts of the world have little 
or no access to harm reduction or drug treatment in prisons, though drug use and unsafe sex, including rape, continue.  
Availability of other forms of health care, including HIV and TB treatment and mental health care, is usually poor, as 
well.  See, for example, Canadian HIV/AIDS Legal Network (2004).  Prison Needle Exchange: Lessons from a 
Comprehensive Review of International Evidence and Experience.  www.aidslaw.ca. Belenko S, Peugh J (2005).  
Estimating drug treatment needs among state prison inmates.  Drug and Alcohol Dependence 77.  Stern V (2001).  
Problems in prisons worldwide, with a particular focus on Russia.  Annals of The New York Academy of Sciences, 
Vol. 953.  Sarang, A, Rhodes, T, Platt, L et al (2006).  Drug injecting and syringe use in the HIV risk environment of 
Russian penitentiary institutions: Qualitative study.  Addiction, 101.  UNAIDS (1997).  Prison and AIDS.  Geneva.  
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that inhibit IDUs’ ability to use harm reduction services and practice safer drug use. 119  
Even when the police are not the perpetrators, drug users often do not report crimes out 
of a reluctance to attract potentially damaging attention, or out of the often justified belief 
that law enforcement officials do not take crimes against drug users and sex workers 
seriously.  This further increases women drug users’ vulnerability to physical and sexual 
violence and exploitation that can increase their risk of HIV.   
 
Lack of confidentiality from service providers and police 
 
In many countries of Eastern Europe and Central Asia, court- or police-ordered drug 
treatment, arrest on a drug-related charge, or even admission of drug use to a doctor can 
lead to registration as a drug user, which can have a range of detrimental consequences, 
including ineligibility for free ARV treatment and public housing, loss of drivers’ 
licenses, and police harassment.120  Registration can be especially threatening to women, 
whose custody of their children can be jeopardized and who, as discussed earlier in this 
paper, face particularly severe stigma and discrimination when their drug use is exposed.  
It can lead women to avoid many types of services, from drug treatment to harm 
reduction to prenatal care.  In Russia, a diagnosis of drug addiction is legal grounds for 
loss of parental rights,121 providing women with a clear reason to avoid drug treatment.  
Research in Ukraine found that women had difficulty using harm reduction services 
because of registration requirements that raised concern about stigma and loss of 
custody.122   
 
A lack of safeguards to protect women drug users’ privacy discourages contact with 
institutions and disclosure of drug use.  Whether out of carelessness, poor planning, or 
the assumption that women drug users do not have a right to confidentiality, caregivers 
often reveal women’s drug use and HIV status, whether intentionally or inadvertently, to 
family members and others.  Some health care providers intentionally disclose a patient’s 
status to others, including the police or government agencies.  Sometimes information 
about drug use and HIV are not kept confidential—for instance, the outside of a patient’s 
medical file states that she is a drug user, or the beds of HIV-positive patients are 
marked.123  The organization of hospital wards can also reveal a patient’s drug use—for 
example, if babies born to active drug users are kept in a separate ward, visitors know 
immediately that mothers used drugs during pregnancy.124  This can be deeply upsetting 
to women who have gone to great lengths to conceal their drug use from parents, 
partners, or friends, let alone the police or other authorities, and can compromise their 
relationships with their families, their custody of their children, and their physical safety.   
                                                                                                                                                 
118 Csete J., Cohen, J. Op. cit. 
119 Human Rights Watch, Lessons not learned: Human rights abuses and HIV/AIDS in the Russian Federation. Op cit. 
120 Personal communication, Yury Ivanov, 2006.  Rhodes, T, Platt, L, Sarang, A, Vlasov, A, Mikhailova, L, Monoghan, 
G (2006). Street policing, injecting drug use and harm reduction in a Russian city: A qualitative study of police 
perspectives.  J of Urban Health: Bulletin of the New York Academy of Medicine, 83(5). 
121 Lev Levinson.  Personal communication, 2007. 
122 Centre for Social Expertise of the Institute of Sociology at the National Academy of Science of Ukraine (2005).  A 
review of work with injecting drug users in Ukraine in the context of the HIV/AIDS epidemic.  Kiev.   
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124 Klee et al (2002). Op cit. 
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Marginalization within services 
 
In many parts of the world, harm reduction and drug treatment programs have mostly 
male clients and do not provide services specific to women’s needs, offer spaces or times 
for women, or have safeguards to ensure that women are not threatened by men in the 
program.125  This can create an intimidating, alienating, and unsupportive environment 
for women, particularly since women drug users are more likely than other women or 
male drug users to have experienced physical or sexual violence, and are in particular 
need of a safe, non-threatening environment.126  Many programs have few, if any, women 
outreach workers,127 which can impede their ability to attract women to their services.  At 
the largest harm reduction program in Iran, only 2-5 percent of clients are women, and 
the director reports that scarce resources and high demand force programs to focus on 
men, while patriarchal social structure and powerful stigma against women drug users 
make them last in line to receive services.128  In Sichuan, China, substantially fewer 
women IDUs than men reported having access to methadone maintenance, in part 
because many of them were migrant sex workers and therefore ineligible for programs129 
(China has since eliminated residency registration requirements for methadone 
treatment).   
 
Worldwide, women appear to be underrepresented in drug treatment, and many inpatient 
drug treatment services have no special sleeping areas, bathrooms, or other spaces for 
women.130   Failure to provide specialized services or to create a space in which women 
feel comfortable may deter women from accessing services, further reducing the number 
of women clients, making women drug users even less visible to service providers, and 
making it even less likely that programs will develop gender-sensitive services.   
 
Barriers to access to drug treatment 
 
Though the desire to give birth to healthy babies, be good mothers, and retain custody of 
children is one of the most powerful motivators to enter drug treatment, lack of child care 
is the most significant obstacle to women wishing to enter drug treatment.131  Many 
women do not want to leave their children for weeks or months while they undergo 
inpatient treatment, and studies show that women are more likely to remain and succeed 
in treatment when they retain custody of their children.132   Even if they are willing to be 
                                                 
125 Personal communication, Grzegorz Wodowski, Monar (Poland), 2006; Ingrid Irawati Atmosukarto, Laura 
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130 UNODC (2004).  Substance abuse treatment and care for women.  Op cit. 
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132 UNODC (2004).  Substance abuse treatment and care for women.  Op cit. 
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separated from their children during treatment, many women do not have the option to do 
so.  Women are children’s primary caregivers in all sectors of society, and women drug 
users are less likely to have the financial resources and social support networks to allow 
them to leave their children for a prolonged period.133  Yet few drug treatment or harm 
reduction programs have the child care services, flexible hours and regulations, short 
waiting periods, and mobile delivery of medications that would make it easier for women 
to fit visits into their schedules.  In Eastern Europe, Central Asia, South and Southeast 
Asia, China, and Africa, effective outpatient drug treatment—notably medication-assisted 
treatment—is available to only a tiny proportion of those in need.134  In Russia, home to 
two million IDUs, methadone and buprenorphine are unavailable.  Worldwide, only a 
handful of drug treatment programs have child care facilities or a child-friendly 
environment that would allow women to bring their children with them on visits.135  
Inpatient treatment with child care would help some women, but even given the 
opportunity, some women do not want their children to spend long periods in a treatment 
center, and others do not wish to undergo treatment in the presence of their children.136 
Lack of child care can also limit women’s access to harm reduction services, since 
women may not be able to leave their children for trips to a service site.  In general, 
women require programs that take into account domestic responsibilities.  In an 
Australian survey, women were less likely to drop out of drug treatment programs that 
were flexible, had few rules, and offered individualized care.137    
 
Drug treatment in many countries is prohibitively expensive for many people of both 
sexes, but because women are more likely to be financially dependent on others and to 
earn less, they may have even greater difficulty than men do in paying for drug treatment.  
Especially in resource-poor settings, families tend to invest less in female family 
members than in males,138 and this can translate into a reduced willingness to pay for 
drug treatment.   
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Designing Services for Women Who Use Drugs 
 
The needs outlined in the previous sections show clearly that gender-sensitive services 
for women drug users are necessary.  For example, well-trained, qualified women staff 
and outreach workers will help create a woman-friendly environment.  Special times, 
places, and services for women will serve their needs better and give them a safe space in 
which they feel comfortable.  Fulfillment of basic needs will give women the time, space, 
and safety needed to make positive changes to their drug use and sexual practices.  The 
following section outlines gender-sensitive harm reduction, drug treatment, and sexual 
and reproductive health services for women who use drugs.   
 
Involve women drug users in services and policymaking 
 
Meaningful involvement of women who use drugs in service design and delivery can 
improve the effectiveness and efficiency of health and social services.  The presence of 
other women drug users as staff members and volunteers will make women drug users 
feel more comfortable, less stigmatized and marginalized, and better understood by a 
program.  People who use drugs have “inside knowledge”139 that is essential to an 
informed approach to service provision and policymaking.  For both ethical and practical 
reasons, the involvement of women who use drugs must be the basis of any response to 
this population’s needs. 
 
Greater involvement of women who use drugs can be accomplished in a number of 
ways.140  The overarching goal should be to empower women to contribute ideas and to 
hold real decision-making authority. Agencies serving women who use drugs should, for 
example, be required to establish service-user advisory committees and elect women who 
use drugs to their boards of directors. In the hiring and promotion of staff, including for 
management positions, direct experience of injecting drug use should be considered a 
positive credential in evaluating a candidate. Similarly, research projects that include 
drug users as subjects have a responsibility to involve drug user representatives on ethical 
review boards, to seek consultation with drug users throughout all phases of research, and 
to share results.  There is also a growing body of expertise and experience in conducting 
community-based participatory research.141  Researchers should pursue participatory 
research as a means of both enhancing quality and supporting social justice, particularly 
when focusing on marginalized or otherwise “hard to reach” populations such as women 
who use drugs.  Finally, government and other policymaking bodies should strive to 
include women drug users on relevant committees, involve them in hearings, and 
otherwise support substantive participation.  This includes support to overcome the 
barriers to effective participation that are caused by stigma, discrimination, and health 
concerns. 
                                                 
139 Balian, R and White, C (1998). “Defining the Drug User.” Harm Reduction Communication. Harm Reduction 
Coalition, New York.  http://harmreduction.org/pubs/news/fall98/f98toc.html. 
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Involvement of People Who Use Illegal Drugs. Canadian HIV/AIDS Legal Network. Toronto: 2005. Available online at 
www.aidslaw.ca.  
141 See, for example, Minkler, M and Wallerstein, N (2003). Community Based Participatory Research for Health. San 
Francisco: John Wiley & Sons. 
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Create a woman-friendly environment 
 
Since women drug users are inordinately likely to have experienced violence and often 
feel marginalized and stigmatized even by other drug users, services must strive to create 
a woman-friendly environment. Trained women staff members and volunteers may make 
women feel more at ease, and are essential for women who are not comfortable receiving 
care or treatment from men.  Women’s support groups provide a forum for women to 
discuss their concerns and experiences in a space in which they do not feel marginalized 
or vulnerable to sexual harassment or assault.  Separate space used only by women can 
create a sense of safety and ownership.142   Because so many women drug users have 
experienced sexual violence, it is imperative that programs work to ensure that male harm 
reduction clients are not aggressive or threatening to women clients.  Staff members need 
clear policies, training, and supervision to prevent sexual harassment or sexual 
relationships between staff and clients/patients,143 and to ensure that women can receive 
care in an atmosphere free of any perceived threat.     
 
Help women become more independent 
 
A growing body of evidence suggests that in order to be effective, HIV prevention 
interventions must address risk factors beyond the level of the individual.144  Such 
interventions are especially important for women, for whom sexual and familial 
relationships, experiences of sexual and physical violence, and social and structural 
power imbalances play a greater role in drug use and HIV risk.  Couples counseling can 
help women to negotiate a reduction in sexual and injection-related risk behavior with 
their partners, and address the power dynamics that underlie these risks.  Women’s 
support groups, specialized counseling, and women outreach workers can help women 
drug users to negotiate safer injecting, while gender-sensitive syringe exchange and 
outreach can provide women with injection supplies and reduce their reliance on men.  
Safer injection education can help women learn to inject themselves safely without 
assistance.  Strong connections between harm reduction programs and women’s shelters, 
services for survivors of domestic violence, and rape and domestic violence prevention 
programs can reduce women’s vulnerability to their partners.  Job training and placement 
assistance can help women become financially independent and avoid damaging 
economic dependence on abusive partners.  Legal aid programs can help women access 
legal remedies for abuse, exploitation, unjust incarceration, and loss of custody of their 
children, while sending the message that women drug users cannot be abused with 
impunity.  Self-defense classes can help women protect themselves from assault.   
 
                                                 
142 UNODC (2004).  Substance abuse treatment and care for women.  Op cit. 
143 For an insightful discussion about the need to prevent sexual relationships between staff and clients, and about the 
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144 See, for example, Miller, M & Neaigus, A, op cit; Rhodes, T, Singer, M, Bourgois, P, Friedman, SR, Strathdee, SA 
(2005).  The social structural production of HIV risk among injecting drug users.  Social Science and Medicine, 61, 
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For many women drug users, poverty lies at the heart of risk.  Many successful harm 
reduction programs help fulfill basic needs, showing women that they care about their 
immediate well-being by providing food, shelter, transitional housing, clothing, and 
showers.  Tampons, sanitary pads, and other useful women’s products can be provided 
along with standard safe injecting kits to attract and retain women and show them that 
programs are aware of their needs and recognize that women use drugs, too.  For 
pregnant and parenting women, some programs have provided prenatal vitamins and 
nutritional counseling, children’s clothing and other items, childhood immunizations, 
infant formula and food, pediatric consultations, parenting support, and help dealing with 
social services.145    
 
Race, ethnicity, and lack of resident status are often crucial factors in whether a woman is 
poor, homeless, in prison, or without access to health services.146 Long experience of 
discrimination and disenfranchisement can have a negative impact on the self-esteem and 
mental health of racial, ethnic, and sexual minority women, increasing the risk of 
problematic substance use and high risk behaviors. Service providers need to ensure that 
they are creating an inclusive space by employing staff members who reflect their clients’ 
background and providing services that respond to their needs as they are shaped by 
racial, ethnic, national, or sexual identity. 
 
Many successful services for women drug users provide case management to help women 
make and keep appointments with doctors and social workers and to navigate the often 
labyrinthine landscape of health and social services. This can include long-term, 
individual counseling and assistance in navigating health and social services, 
accompaniment to appointments, and patient advocacy.    
 
Make programs available for mothers 
 
Since lack of child care is the greatest obstacle to women’s access to drug treatment,147 
providing child care and allowing children to stay with their mothers in inpatient drug 
treatment facilities can increase women’s willingness and ability to enter treatment.  The 
many women who do not need or want inpatient treatment, or who cannot or will not 
bring children with them to treatment, need access to effective outpatient treatment that 
interferes as little as possible with their child care, work, and household responsibilities.  
If possible, drug treatment and harm reduction programs should create safe, clean, age-
appropriate spaces where children can stay while their mothers receive care.  However, it 
should be noted that this may be difficult for programs with limited resources; the 
presence of children may be unwelcome to other clients or to the mothers themselves; the 
presence of children at some service sites may pose a prohibitive safety risk; and mothers 
may not want their children to know that they are drug users.  These limitations make it 
especially important that programs work with women to provide services that do not 
interfere with their family responsibilities (see below). 
                                                 
145 For an example of such a program, see the website of Sheway, a program for pregnant and parenting drug users in 
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Provide low-threshold syringe access, mobile services, and secondary exchange 
 
Some women may be unable to visit harm reduction sites because of child care and other 
domestic responsibilities, because their partners oppose it, because they cannot afford the 
cost of transportation to a site, because they are unwilling to be identified as a drug user, 
or for other reasons.  There are a number of changes that harm reduction sites, with the 
support of policymakers, can use to overcome these obstacles.   
 
The frequency of syringe exchange visits can be reduced by elimination of limits to the 
number of syringes that can be exchanged at one time.  Visits of all types can be made 
more convenient by extending working hours or making them more appropriate to client 
schedules, providing mobile services and outreach to locations easily accessible to 
women drug users, and minimizing waiting times.  Making syringes available over the 
counter in pharmacies, without the threat of police harassment or a pharmacist’s breach 
of confidentiality, can also make syringes more accessible to women by providing a 
discreet source in women’s neighborhoods, though stigma may still deter some women.  
Providing harm reduction and drug user-oriented sexual and reproductive health services 
through other women-centered services (for instance, women’s shelters or domestic 
violence prevention services) can provide access to those unwilling or unable to visit a 
harm reduction or drug treatment site.  Particularly in small communities, services should 
be positioned in such a way that entry is not tantamount to disclosure that one uses drugs. 
 
Secondary syringe exchange, when a woman obtains and returns syringes through 
another person who visits a syringe exchange site, can increase access for women unable 
to use syringe exchanges directly.148  For example, a woman who is unwilling to be seen 
at a syringe exchange because of stigma, or who is unable to visit the exchange because 
she has no one to take care of her children while she is gone, can get clean syringes from 
a partner or friend.  While secondary exchange can improve women’s access to syringes, 
it does not in itself improve access to other harm reduction services, and, particularly if 
women are receiving syringes from a sexual partner, can perpetuate patterns of 
dependence.  If a harm reduction program chooses to promote secondary exchange, it 
should also maintain services such as outreach programs, home visits, and hotlines to 
ensure that women do not remain invisible to providers, and that they have access to 
services beyond sterile syringes.   
 
Certain services have the same benefits as secondary exchange while allowing providers 
to make contact with women drug users.  For example, home delivery of clean injection 
equipment can help programs reach women and give outreach workers an opportunity to 
assess a woman’s circumstances in person, and offer her additional services and support.  
Mobile harm reduction and drug treatment services can improve access for those unable 
to leave their own neighborhoods.  Hotlines can provide anonymous, convenient 
information to women reluctant to visit harm reduction sites or disclose their identity.   
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Incorporate sexual and reproductive health into harm reduction services 
 
Incorporation of sexual health services into harm reduction programs can attract women 
to services and help them protect themselves from HIV, STIs, and unwanted pregnancy.   
Integrated services can provide compassionate, non-stigmatizing counseling and access to 
drug treatment and prenatal care for pregnant women.  Programs can educate women and 
their partners about the continued importance of using contraception even while using 
drugs, and of using both condoms and sterile injection equipment with sexual partners.  
They can provide high-quality male and female condoms and other forms of 
contraception.  Rather than viewing sexual and injection-related HIV transmission as 
separate risks in need of individual interventions, services should recognize the 
synergistic relationship between the two and support women as they work to reduce such 
risks.   
 
Gynecological consultations at harm reduction sites can provide women with low-
threshold access to care from a doctor who is accustomed to working with drug users, is 
accustomed to their needs and concerns, and will not stigmatize or reject them.  If this is 
not possible, programs can provide clients with referrals to obstetrician-gynecologists 
who work with drug users and can be trusted to provide appropriate care.  Many 
programs provide staff to accompany women to their doctor’s appointments.  This can be 
helpful for women who are deterred by experienced or anticipated stigma from providers, 
and for women whose lives are chaotic or who have mental health issues and have 
trouble remembering and keeping appointments.   
 
Provide gender-sensitive drug treatment 
 
Effective drug treatment can help women manage, reduce, or cease drug use, injection, 
and equipment sharing, and can reduce sexual risk by making women less likely to be 
high or in withdrawal when making sexual choices.  But in order to be effective, entry to 
treatment must be available without long waiting periods, daunting paperwork, or 
residency requirements.  Treatment cannot have inflexible rules that promote dropout by 
punishing relapse or refusing to work around responsibilities or concerns, such as 
dependent family members or abusive partners, which may interfere with a patient’s 
adherence to a program.  Low-threshold medication-assisted treatment without onerous 
admission requirements and with mobile delivery units or take-home doses is more 
accessible for all drug users, but it is particularly valuable for opiate-dependent women 
whose child care and household responsibilities may make it difficult for them to visit a 
clinic every day at a fixed time or to undergo inpatient treatment, and whose attendance 
at an methadone or buprenorphine clinic may be especially stigmatizing.   
 
By helping women to avoid withdrawal and overdose, reduce or cease injection and illicit 
drug use, stabilize their lives, and improve their health, methadone maintenance treatment 
(MMT), which is safe for use during pregnancy, is an essential tool in helping opiate 
users to have healthy babies.  It is widely recognized as the treatment of choice for 
opiate-dependent pregnant women.149  After birth, medication-assisted treatment’s 
                                                 
149 UNODC (2004).  Substance abuse treatment and care for women.  Op cit. 
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stabilizing effects can make it easier to mother.  In order to minimize HIV risk and drug-
related harm during pregnancy, women need access to MMT on demand.  Drug treatment 
providers and obstetrician-gynecologists should be trained in methadone maintenance for 
pregnant and parenting women, including the possibility of adjusted doses during 
pregnancy, management of neonatal abstinence syndrome, and breastfeeding during 
methadone treatment.150  When women are hospitalized during pregnancy, they should be 
given their methadone discreetly and according to their usual schedule.  All obstetric 
clinics should have non-punitive, non-threatening, evidence-based policies and 
procedures concerning drug use and treatment during pregnancy.   
 
Though there have not yet been large-scale trials, it appears that buprenorphine is also 
safe for use during pregnancy.151  Buprenorphine providers and obstetrician-
gynecologists should be educated on its use during pregnancy.  Oral slow-release 
morphine has also been used safely and successfully during pregnancy.152   Where no 
form of maintenance treatment is available, advocates should press to introduce its use 
during pregnancy.  Because it is clearly vital to the survival and health of the fetus, 
countries may be willing to make a special exception for methadone or buprenorphine 
use during pregnancy.  For instance, until the early 1990s, Germany only permitted the 
use of methadone for drug users who met very narrow criteria, but one of the exceptions 
was for pregnant women.153 
 
Finally, measures by governments and international donors to make evidence-based drug 
treatment affordable for all who need it will improve women’s access.  
 
Provide integrated harm reduction programs for sex workers who use drugs 
 
IDU sex workers need services that do not treat sexual and injection-related risk in 
isolation, but address the ways in which they interact.  Programs should provide sterile 
injection equipment, safe injecting information, condoms, and other harm reduction and 
sexual health interventions, but must also work to alleviate the underlying causes of risk 
behavior.  Services to reduce drug-related risk can also reduce sexual risk.  For example, 
effective drug treatment to help sex workers avoid being high or in withdrawal during a 
transaction, or to reduce their need to generate income to support an illicit drug addiction, 
will help them avoid sexual risk-taking.   
 
In areas where there is an overlap between injection drug use and sex work, injection-
related prevention must be integrated into services for sex workers.  Being known as an 
IDU may make it more difficult for sex workers to attract clients, so services for sex 
workers should include discreet syringe exchange and other harm reduction services.  
                                                 
150 UNODC (2004)Substance abuse treatment and care for women.  Op cit. 
151 Lacroix, I, Berrebi, A, Chaumerliac, T, Lapeyre-Mestre, M, Montastruc, JL, Damase-Michel, C (2004). 
Buprenorphine in pregnant opioid-dependent women.  Addiction, 99, 209-214.; Comer, V & Annito, W (2004). 
Buprenorphine: A Safe Method for Detoxifying Pregnant Heroin Addicts and Their Unborn.  Am J on Addictions, 13, 
317-318.  
152 Fischer, G, Jagsch, R, Eder, H et al (1999).  Comparison of methadone and slow-release morphine maintenance in 
pregnant addicts.  Addiction 94(2).   
153 Michels, II, Stover, H, Gerlach, R (2007).  Substitution treatment for opioid addicts in Germany.  Harm Reduction 
Journal, 4:5.   
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Likewise, harm reduction programs should include services for sex workers where 
applicable.  In both cases, programs should employ staff members and outreach workers 
who are familiar with the community of sex workers who use drugs, and who are 
comfortable addressing the intersection of sex work and drug use.154     
 
Connect with domestic violence and rape prevention services 
 
In order to be truly accessible, services (as well as policies and advocacy) must address 
the prevalence of violence in women drug users’ lives.  Women may not be able to 
practice safer sex or injection, visit a syringe exchange site, enter drug treatment, or make 
their own decisions about childbearing because of violence or threats of violence from 
their partners. 
  
At the moment, few drug-related services are linked with women’s shelters and services 
for battered women and rape survivors, if either type of service exists at all.  In some 
Russian cities, for example, women’s shelters refuse to accept drug users.155  Given the 
disproportionate number of women drug users in need of such services, and given that 
violence is a principal obstacle to their access to life-saving harm reduction, drug 
treatment, and sexual and reproductive health services, the integration of these two types 
of services is direly needed.  Existing programs should collaborate to develop strong links 
to one another, and to ensure that each has staff with the skills, resources, and experience 
needed to work with women drug users who have experienced violence.  Harm reduction 
programs should train all staff members to recognize and respond to signs that a woman 
is experiencing violence or suffering from post-traumatic stress.  Women’s shelters 
should welcome drug users and offer strong connections to harm reduction and drug 
treatment services and education, or provide them on-site. 
 
Educate mainstream providers 
 
Mainstream medical services are generally uninformed and unaccommodating where 
drug use is concerned, and as long as drug users remain stigmatized and marginalized, 
specialized services will be necessary.  Specialized programs serving women drug users 
should make an effort to provide as many services as possible on-site.  But there is a limit 
to how many medical services can be provided at a specialized program, and some 
women will make contact first with mainstream providers.  It is essential, therefore, that 
curriculums for primary care providers, adolescent care providers, obstetrician-
gynecologists, psychiatrists and psychologists, and social workers include training in the 
signs and risks of problem drug use and how to offer effective drug treatment, accurate 
information, and referrals to harm reduction services.   
 
 
 
 
                                                 
154 For comprehensive discussions of service design and policies for sex workers, please refer to the resources cited at 
the beginning of this paper. 
155 Personal communication, Nadezhda Fedoseeva, Anti-AIDS Foundation Penza, 2007. 
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Adapt programs based on available resources 
 
No harm reduction, drug treatment, or women’s programs have unlimited resources, and 
many face a chronic shortage of funds, staff, and materials which may make gender-
sensitive services seem an unattainable luxury.  Fortunately, many of the changes needed 
cost little or nothing.  For example, services can make an effort to ensure gender balance 
among staff, to hire staff members with experience in women’s issues, and to be vigilant 
in preventing sexual harassment or gendered intimidation in services.  It costs little or 
nothing to have a designated “ladies’ night” when women can come to a service center 
with the confidence that they will be, for once, in the majority.  Distributing literature or 
harm reduction kits targeted to women is inexpensive, disseminates valuable information, 
and sends the message that services are aware of women drug users and care about their 
needs.  Provided that governments make it accessible, outpatient MMT is the most cost-
effective option for those dependent on opiates and is also an excellent option for women, 
particularly if it is provided at convenient times and locations, and if take-home doses are 
allowed.  Inpatient treatment of STIs is a costly and most often unnecessary measure that 
discourages treatment; its elimination should be a priority.   
 
Added services are meaningless if women are not using them.  Access should be the first 
consideration in weighing the benefit of new programs given financial constraints.  If 
there is a choice of extending service hours or offering new services during hours when 
women cannot come, extending hours is a better use of funds.  Likewise, if a key barrier 
to women’s access is that they cannot leave home long enough to come to a syringe 
exchange point, it may be better to provide mobile exchange than to have a gynecologist 
available at the site.  Involving women drug users in the design and implementation of 
new services will help ensure that programs are practical and accessible.   
 
Policy changes that benefit women drug users are more cost-effective than existing 
punitive policies that depend on incarceration and discourage preventive care.  Analysis 
in the United States has concluded that both outpatient and long-term residential drug 
treatment services cost only a fraction of the price of incarceration, and an even smaller 
fraction when the costs of foster care, often necessary when mothers are imprisoned, are 
included in the cost of incarceration.  Incarceration often adds to the trauma and physical 
and mental health problems that contributed to women’s drug use in the first place, 
increasing women’s vulnerability, need for future assistance, and likelihood of repeat 
incarceration.  Moreover, it damages families and communities and increases children’s 
vulnerability, generating further costs to the state.156  Policy changes to reduce 
incarceration and increase access to drug treatment are not only compassionate, but 
pragmatic and cost-effective. 
 
 
 
 
 
 
                                                 
156 ACLU et al. Caught in the Nets. Op cit. 
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Shaping Policy to Protect Women’s Health 
 
For policymakers and health care systems: 
 
• Develop policies that encourage women to seek care 
 
For many women drug users, fear of punishment or loss of custody of children is a 
central reason to avoid drug treatment, harm reduction services, and prenatal care.  Shape 
policy to encourage women drug users to seek care.  Rather than punishing women who 
use drugs, give them access to high-quality, gender-sensitive drug treatment services, 
including methadone or buprenorphine maintenance.  (See recommendations for service 
design, above.)  Protect the health of women and their children by supporting accessible 
harm reduction services, sexual and reproductive health care, and violence prevention 
services.   Ensure that residency status, drug use, drug user registration, or financial 
means are not obstacles to women’s access to life-saving care.  When developing 
regulations for syringe exchange and drug treatment, be sure that they permit services 
such as mobile or secondary exchange and take-home doses, which can be beneficial for 
women drug users.  Involving women who use drugs in policymaking will help ensure 
that policy responds intelligently to women drug users’ needs. 
 
• Protect women drug users’ rights 
 
Ensure that women drug users can benefit from the full protection of the law.  Fear of the 
police or the courts should not deter women from accessing services or reporting crimes 
committed against them.  Train police on the rights of drug users and sex workers, hold 
law enforcement agents accountable for abuses, and provide safe mechanisms for drug 
users and sex workers to protest abuse.  
 
• Protect women drug users’ confidentiality 
 
Women drug users are often concerned about confidentiality, as they face special stigma 
and potential loss of their children if their drug use is revealed.  Develop and enforce 
legal protections of patient confidentiality, so that women can go to the doctor without 
fear that their drug use will be disclosed to police, family, employers, or others.  
Encourage women to seek HIV and STI testing by ending mandatory testing and routine 
testing without counseling or consent.  Make confidential, voluntary counseling, testing, 
and treatment for HIV and STIs available to all women.  Allow women to enter drug 
treatment without fear that they will lose custody of their children.   
 
• Make harm reduction and drug treatment available in women’s prisons 
 
Women are disproportionately likely to be imprisoned on drug-related charges, and 
incarceration can increase the HIV risk of women drug users, many of whom continue to 
use drugs in prisons.  Women also need services to help them protect themselves after 
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release.  Provide syringe exchange, evidence-based drug treatment, including methadone 
or buprenorphine, and sexual and reproductive health services in women’s prisons, and 
provide links to services for those who have just been released.  
 
• Incorporate women drug users’ needs into guidelines and targets 
 
Ensure that women drug users’ needs are included in national strategies to respond to 
HIV and drug use.  In national guidelines on HIV and drug use, acknowledge and address 
the needs of women, and set specific targets for the provision of gender-sensitive harm 
reduction, drug treatment, and sexual and reproductive health services for drug users.  
Include specific targets for women drug users’ services in plans to achieve Universal 
Access to HIV/AIDS Prevention, Treatment, Care and Support. 
 
• Structure health care systems to provide integrated care 
 
Women drug users often have multiple health needs and few resources with which to 
pursue care.  Support gender-sensitive harm reduction services that provide or connect to 
sexual and reproductive health care.  Ensure that pregnant drug users who test positive 
for HIV have immediate, easy access to PMTCT services and counseling.  Ensure that all 
pregnant drug users have immediate access to drug treatment.  Strengthen connections 
between women’s services, such as domestic violence prevention, and harm reduction 
projects, and coordinate drug-related services with social services.  Whenever possible, 
provide outpatient treatment for STIs so that women will not avoid treatment because 
they do not wish to be hospitalized. 
   
• Educate providers 
 
Educate health care professionals, especially obstetrician/gynecologists, on care and 
treatment for women drug users, including risk reduction strategies during pregnancy, 
PMTCT, medication-assisted treatment during pregnancy, and nonjudgmental support of 
women drug users.  Cultivate a tolerant attitude toward injecting drug users, particularly 
women, among health care providers and health care managers.    
 
For researchers: 
 
• Research the needs of women drug users 
 
Research on women drug users is still inadequate in many countries, and more 
quantitative and qualitative research on drug use, HIV, and sexual and reproductive 
health among women drug users is needed.  Data collection from pilot programs can 
show which harm reduction, drug treatment, and sexual and reproductive health 
interventions serve women drug users best (e.g., attract them to services, retain them in 
contact with services, and improve health outcomes). When doing research that involves 
women drug users, involve women drug users on ethical review boards and in 
consultations, and share results with women drug users.   
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For donors: 
 
• Support services for women drug users  
 
Fund and advocate for the services described above.  Urge countries to respect women 
drug users’ right to sexual and reproductive freedom, and to health care and mainstream 
social services.  Include women drug users in service and research design and advocacy, 
and include requirements for the participation of women drug users in funded activities 
